Abstract

The population pharmacokinetics of doxorubicin were evaluated based on a mixed-effect model using the NONMEM (VI) program. Doxorubicin in plasma was measured using high-performance liquid chromatography. Plasma concentration measurements (85 plasma samples) of doxorubicin from 28 patients with cancer receiving doxorubicin (with other co-medication) ranging from 20–120 mg by infusion over 1–2 h were analyzed according to a two-compartment model both in FO and FOCE methods. Additive proportional error model was used to describe inter-individual and residual variability. The influence of covariates such as age, body surface area, gender, and clinical laboratory values (SGOT, SGPT) on total body clearance (CL) and volume of distribution (Vd) were examined. No covariate was found to affect the CL and Vd of unchanged doxorubicin. The CL and Vd estimated by FO method were 1.42 L/h and 51.1 L, respectively, and FOCE method are 1.43 L/h and 51.4 L, respectively. The inter-individual variability for CL and Vd and r...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.